Evidence map›Paper›PMID 31264003›Full record

ArticlePharmaceutical research2019

Utility of High Resolution NMR Methods to Probe the Impact of Chemical Modifications on Higher Order Structure of Monoclonal Antibodies in Relation to Antigen Binding.

Subhabrata Majumder, Andrew Saati, Shibu Philip, Lucy L Liu, Elaine Stephens, Jason C Rouse, Arun Alphonse Ignatius

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Expression ofEPJ web of conferences · 2023
    Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Subhabrata MajumderPharmaceutical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, 63017, USA.
Andrew SaatiAnalytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, MA, 01810, USA.
Shibu PhilipAnalytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, MA, 01810, USA.
Lucy L LiuAnalytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, MA, 01810, USA.
Elaine StephensAnalytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, MA, 01810, USA.
Jason C RouseAnalytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, MA, 01810, USA.
Arun Alphonse IgnatiusPharmaceutical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, 63017, USA. arun.alphonseignatius@pfizer.com.ORCID http://orcid.org/0000-0002-7342-044X
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAn understanding of higher order structure (HOS) of monoclonal antibodies (mAbs) could be critical to predicting its function. Amongst the various factors that can potentially affect HOS of mAbs, chemical modifications that are routinely encountered during production and long-term storage are of significant interest.

methodsTo this end, two Pfizer mAbs were subjected to forced deamidation stress for a period of eight weeks. Samples were aliquoted at various time points and high resolution accurate mass liquid chromatography-mass spectrometry (LC-MS/MS) was performed using low-artifact trypsin digestion (LATD) peptide mapping to identify and quantify chemical modifications. 2D backbone amide and sidechain methyl NMR spectra were acquired to gauge the effect of HOS changes upon chemical modification. Differential scanning calorimetry was also performed to assess the effect of thermal stability of mAbs upon modification. Finally, functional studies via target-binding based ELISA were performed to connect HOS changes to any loss of potency.

resultsThe extent of deamidation in the mAb domains were quantified by LC-MS/MS. The HOS changes as obtained from 2D NMR were mostly localized around the affected sites leaving the overall structure relatively unchanged. The antigen-antibody binding of the mAbs, in spite of deamidation in the Fab region, remains unchanged.

conclusionThis case study provides an integrated approach of relating chemical modifications in mAb domains with possible changes in HOS. This can be potentially used to assess a possible loss of potency within the structure-function paradigm of proteins in an orthogonal manner.

Indexed as

Antibodies, MonoclonalAntigen-Antibody ComplexChromatography, High Pressure LiquidMagnetic Resonance ImagingProtein BindingProtein ConformationTandem Mass SpectrometryAntibodies, MonoclonalAntigen-Antibody Complexdeamidationhigher order structure (HOS)monoclonal antibodiesnuclear magnetic resonancepotency

Identifiers

PMID31264003
OpenAlexW2955573826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.